# The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis

> **NCT00646425** · PHASE2 · TERMINATED · sponsor: **Cerimon Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Non-infectious Uveitis

## Interventions

- **DRUG:** Basiliximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00646425
- **Lead sponsor:** Cerimon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2010-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00646425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00646425, "The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT00646425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*